Interview with Worwick Anderson, NHMRC,
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Address: Level 1, 16 Marcus Clarke Street, Canberra,Australia
Tel: +61 2 6217 9000
The NHMRC is Australia’s NIH equivalent, being the big government funding body for health and medical research. We have always had in our portfolio a full range of health and medical research. Some funding bodies like the UKMRC are more biomedical, but the NHMRC has always been concerned with public health and health services research, so it’s a very broad portfolio. The NHMRC is more than a funding body, and strives to improve the lives of all Australians. For example, the organization publishes evidence-based guidelines for clinical practice and public health. An example of the latter is the current work being completed in finalizing safe alcohol-drinking guidelines, around which there is some controversy as we speak, because the message from science and what the public would like to believe do not always align.
The NHMRC also manages research and clinical ethics systems for Australia, publishing guidelines in this regard. Overall, it’s a fantastic organization of great importance to the health and wealth of the country. The NHMRC was a part of the Department of Health until July of 2006, when, coinciding with my arrival, we became an independent government body within the health portfolio, reporting directly to the Minister, which gives us all sorts of opportunities. Other aspects of the NHMRC portfolio include acting as the body under the Australian parliament act around stem cells, to issue licensing for cloning and embryo experimentation.
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Your distinguished career in health research leadership and management has seen you through a variety of prestigious positions, not to mention the Order of Australia. Most recently you were appointed…
You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine,…
In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We…
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
See our Cookie Privacy Policy Here
